Sugammadex

---

Identity

Chemical Profile

---

Background

History

For decades, reversing neuromuscular blockade meant using neostigmine, an acetylcholinesterase inhibitor that floods the synapse with ACh until it out-competes the blocking agent. It works for moderate blockade, but it hits a ceiling. At deep levels there simply are not enough available receptors for ACh to matter, and neostigmine’s muscarinic side effects require coadministration of an anticholinergic. The field needed something fundamentally different. Using cyclodextrins (hollow sugar rings already known in pharmaceutical chemistry) as selective drug encapsulators was the conceptual leap that made sugammadex possible.

• Late 1990s

  Researchers at Organon (Netherlands) begin exploring whether cyclodextrin derivatives could be engineered to selectively encapsulate drug molecules as the active pharmacological mechanism. The target is rocuronium, their own drug, whose fast onset made it ideal for RSI but whose long duration was an intraoperative liability without a reliable reversal strategy.

• 2002

  The compound designated Org 25969, later named sugammadex, is identified as the lead candidate after iterative structural modifications to the gamma-cyclodextrin scaffold. Early animal studies show rapid, complete reversal of rocuronium-induced blockade without muscarinic side effects. The concept of a Selective Relaxant Binding Agent (SRBA) is formalized.

• 2008

  The European Medicines Agency (EMA) approves sugammadex (brand name Bridion) in the EU. The FDA rejects the initial US application after concerns emerge about hypersensitivity reactions, including anaphylaxis, in a subset of patients. The drug enters widespread European practice while the US waits seven more years.

• 2015

  The FDA approves Bridion (Merck) following additional safety data and post-marketing surveillance from Europe. US adoption is rapid. Rocuronium, already the fastest-onset non-depolarizing NMBA, now has a reliable escape hatch, fundamentally changing how providers approach RSI and deep intraoperative blockade.

• 2016 to Present

  Updated guidelines emphasize sugammadex as the preferred reversal agent when deep or moderate blockade is present. Residual neuromuscular blockade (RNMB), previously underappreciated as a cause of postoperative respiratory complications, comes under fresh scrutiny, and the adequacy of reversal becomes a traceable, documentable standard. This shift is still playing out in clinical guidelines and courtrooms alike.

---

Pharmacology

How It Works

To understand sugammadex, you first need to understand what it’s reversing. Steroidal NMBAs like rocuronium and vecuronium work by competing with acetylcholine (ACh) at the nicotinic receptors on the motor end plate. Those receptors normally open ion channels when ACh binds, triggering muscle contraction. When rocuronium occupies the receptor instead, ACh cannot bind, the channel does not open, and the muscle stays paralyzed. There’s no metabolism or breakdown happening in real time, just competitive occupation at the receptor.

Sugammadex bypasses that competitive dynamic entirely. Its hollow core has a hydrophobic interior that fits the steroidal ring of rocuronium like a key in a lock, and the carboxymethyl thioether side chains add van der Waals and electrostatic interactions on top. The result is an extraordinarily stable 1:1 host-guest complex. When sugammadex is injected IV, the plasma concentration of free rocuronium drops almost instantly. That steep concentration gradient pulls rocuronium away from the neuromuscular junction. Nothing is competing for the receptor; the equilibrium has just shifted so far toward encapsulation that free rocuronium can’t stay unbound. The motor end plate clears, ACh can bind again, and muscle function returns.

This is categorically different from neostigmine, which doesn’t touch rocuronium at all. It just floods the synapse with more ACh by blocking acetylcholinesterase. Neostigmine has a ceiling: at deep levels of blockade there are not enough unoccupied receptors for ACh to compete effectively, no matter how much accumulates. Sugammadex has no such ceiling, which is why it can reverse profound blockade (even immediately after an intubating dose of rocuronium) while neostigmine at that point would be ineffective or counterproductive.

Dosing at a Glance

Moderate blockade (TOF count 2 or more): ~2 mg/kg  ·  Deep blockade (TOF count 0–1, PTC 1–2): ~4 mg/kg  ·  Immediate reversal of intubating rocuronium dose: 16 mg/kg  ·  Onset: ~2–3 min  ·  Duration: sustained (complex is renally cleared)

---

Anesthetic Practice

Clinical Application

Sugammadex is used whenever a steroidal NMBA needs to be reversed, which in most modern ORs means at the conclusion of nearly every case involving rocuronium. But its most clinically consequential applications go well beyond routine end-of-case reversal.

• Routine end-of-case reversal: Given at the conclusion of surgery to restore full neuromuscular function before extubation. Dose is guided by quantitative TOF monitoring. The T4/T1 ratio tells you exactly how much blockade remains and therefore which dose is appropriate. This is not guesswork anymore, and guidelines increasingly treat it that way.
• Rescue in can’t-intubate, can’t-oxygenate (CICO) scenarios: If a patient receives a full intubating dose of rocuronium (1.2 mg/kg) and the airway cannot be secured, 16 mg/kg of sugammadex can fully reverse the blockade within 2 to 3 minutes, allowing return of spontaneous ventilation. This makes rocuronium a viable alternative to succinylcholine for RSI at institutions where sugammadex is immediately available, since the paralysis is now reversible on demand in a failed-airway emergency.
• High-risk respiratory patients: Patients with obesity, obstructive sleep apnea, myasthenia gravis, or significant pulmonary disease tolerate residual neuromuscular blockade poorly. Even mild RNMB (a T4/T1 ratio below 0.9) impairs upper airway tone and hypoxic ventilatory response enough to meaningfully increase postoperative pulmonary complication risk. Sugammadex’s ability to achieve complete, reliable reversal makes it the preferred agent in these populations.
• Deep blockade reversal: Some surgical conditions (laparoscopic procedures requiring maximal abdominal relaxation, or cases where unexpected patient movement would be catastrophic) benefit from maintaining deep blockade (TOF count 0, PTC 1–2) throughout. With neostigmine, this was essentially irreversible at the moment it was needed. With sugammadex at 4 mg/kg, it isn’t.

Body-Wide Effects

• Cardiovascular: Bradycardia has been reported, though less commonly than with neostigmine. More clinically significant is anaphylaxis, a rare but potentially fatal immune-mediated hypersensitivity reaction estimated at roughly 1 in 3,500 exposures, higher than initially appreciated in clinical trials. The mechanism is IgE-mediated mast cell degranulation, and prior exposure is not required. Epinephrine is the treatment, and providers must be prepared from the moment of administration.
• Respiratory: No direct bronchospasm risk, a meaningful advantage over neostigmine, which increases airway secretions and can trigger bronchospasm in susceptible patients via muscarinic M2/M3 receptor stimulation. Strongly preferred in patients with reactive airway disease.
• CNS: Sugammadex does not cross the blood-brain barrier appreciably. It’s hydrophilic and large (~2,178 Da). No central nervous system effects, no sedative, analgesic, or autonomic properties of its own. What you observe is purely the restoration of neuromuscular function as free rocuronium is captured.
• Drug interaction with hormonal contraceptives: Sugammadex binds progesterone with meaningful affinity, transiently reducing free plasma progesterone levels. The FDA label requires patients using hormonal contraceptives containing progesterone to use an additional non-hormonal contraceptive method for 7 days following sugammadex, equivalent to missing a full week of oral contraceptive pills. Failure to counsel patients about this interaction is an informed-consent failure with direct medicolegal consequences.
• Contraindications and cautions: Severe renal impairment (CrCl less than 30 mL/min) is a significant concern because the sugammadex-rocuronium complex is renally excreted, and accumulation in renal failure introduces uncertain re-dissociation dynamics. The FDA label advises against use in this population. Re-paralysis after sugammadex reversal requires either waiting at least 24 hours or switching to a benzylisoquinolinium NMBA like cisatracurium, which sugammadex cannot reverse.

---

Medicolegal

Litigation Themes

Sugammadex sits at an unusual medicolegal inflection point. Most drug-related malpractice cases involve a drug causing harm. Sugammadex litigation is often the inverse: it’s the failure to use it, or to use it correctly, that generates liability. As sugammadex has become the standard of care for neuromuscular reversal, the gap between what was available and what was done is becoming the central legal question.

• Residual neuromuscular blockade and failure to monitor: A patient is extubated without quantitative TOF confirmation of adequate recovery (T4/T1 ratio 0.9 or above) and develops postoperative upper airway obstruction, aspiration, or hypoxic respiratory failure. The plaintiff theory: quantitative monitoring would have identified the residual blockade, and appropriate sugammadex dosing would have reversed it. This argument is increasingly viable as monitoring guidelines have become more explicit about what adequate reversal means.
• Neostigmine used at deep blockade instead of sugammadex: Administering neostigmine at a TOF count of zero or one is not only ineffective. It can paradoxically worsen neuromuscular dysfunction at very low receptor occupancy. Cases have emerged where providers attempted reversal with neostigmine at deep blockade, it failed, and the delay in recognizing this and switching to sugammadex contributed to a hypoxic event. The question courts will ask: was sugammadex available? If so, why was it not used first?
• Failure to counsel about the contraceptive interaction: This is an informed-consent failure with a concrete, non-anesthetic consequence: unintended pregnancy. The interaction is listed explicitly in the FDA label. If a patient on hormonal contraception receives sugammadex without counseling about the need for backup contraception for seven days, there is a traceable chain from failure to inform to injury. This is a growing concern, particularly in ambulatory surgery centers where preoperative medication reconciliation may be less systematic.
• Anaphylaxis: preparation and response time: Sugammadex-associated anaphylaxis is rare but real, and outcome depends almost entirely on how quickly epinephrine is administered. Cases that generate liability involve delayed recognition or failure to have epinephrine immediately available. The defense is straightforward when documentation shows prompt, correct response. It becomes untenable when the record reflects a lag between symptom onset and treatment.
• Sugammadex as the expected rescue in failed-airway scenarios: As rocuronium-plus-sugammadex becomes the preferred RSI approach at many institutions, cases of anoxic brain injury following difficult intubation now face the question: was sugammadex immediately accessible, and was it administered promptly when the airway could not be secured? The timeline from failed intubation to sugammadex administration to return of spontaneous ventilation is becoming a critical element in case reconstruction.

---

---

References

• Fuchs-Buder T, Schmartz D, Baumann C, et al. Sugammadex versus neostigmine for reversal of neuromuscular block in adults. Cochrane Database Syst Rev. 2023;5:CD013048.
• Ledowski T. Objective monitoring of neuromuscular blockade: a review of its current role in clinical practice. Anaesthesia. 2021;76(suppl 1):e121-e129.
• Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009;110(2):284-294.
• Kopman AF, Naguib M. Laparoscopic surgery and muscle relaxants: is deep block helpful? Anesth Analg. 2015;120(1):51-58.
• Merck Sharp and Dohme LLC. Bridion (sugammadex) prescribing information. U.S. Food and Drug Administration; 2015 (revised).